Eiger BioPharmaceuticals Net Income

Eiger BioPharmaceuticals (EIGR) currently reports a net income of $-75M as of December 2023. That compares with $-97M in the prior-year period — up 22.5% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Eiger BioPharmaceuticals's net income history and peer comparisons.

Eiger BioPharmaceuticals's net income increased from $-97M to $-75M — a 22.5% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eiger BioPharmaceuticals's net income of $-75M is lower than the Healthcare sector average of $17B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eiger BioPharmaceuticals reported $-75M in net income as of December 2023. That compares with $-97M in the prior-year period — up 22.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-75M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.